Vical (VICL) Complets Enrollment in Vaxfectin-Formulated HSV-2 Vaccine Phase 1/2
Tweet Send to a Friend
Vical (NASDAQ: VICL) announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
